Ghada Waly’s resignation offers the UN Secretary-General a chance to appoint a leader who will align UNODC with human rights-based drug policies and the broader UN system.
The INCB’s 2024 report highlights the global failure to ensure equitable access to controlled medicines for pain relief, palliative care, and harm reduction — urging urgent, rights-affirming reforms.
Against a backdrop of global turmoil and multilateral rupture, the 68th session of the CND marked a turning point in the history of global drug policy by deciding to create a panel of independent experts to rethink the global drug control regime.
IDPC marks Human Rights Day 2024 by shining a light on setbacks, key progress and promising avenues to better align drug policies and human rights standards.
The resolution's veneer of consensus betrays deepening fractures in global drug policy debates, as demonstrated by the string of 'disassociation' statements that followed the document's adoption.
Co-founder of IDPC, renowned scholar and beloved colleague and family man, Dave departed on 20 November 2024 after a long and valiant battle with cancer.
IDPC’s new Strategic Plan for 2024-2027 outlines an ambitious approach to advance drug policy reform, addressing pivotal challenges for our movement in relation to funding, equitable regulation, and media impact, to name a few.
The 2024 World Drug Report misrepresents the right to health, diverges from the UN system's own guidance on the matter, and shockingly omits mentioning harm reduction.
The UN system increasingly questions the validity of the 'drug war', embracing harm reduction and decriminalisation — so why is UNODC stuck in the inertia of the past?
